Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats

Journal of Physiology and Pharmacology

Volumn 63, Issue 2, 2012, Pages 201-204

  Tsirella, E ^a   Mavrakanas, T ^b   Rager, O ^b   Tsartsalis, S ^a   Kallaras, K ^a   Kokkas, B ^a   Mironidou Tzouveleki, M ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bone mineral density; Diabetes mellitus; Osteocalcin; Pioglitazone; Streptozocin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; OSTEOCALCIN; PIOGLITAZONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE DISEASE; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAPHYSIS; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMUR; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MALE; METAPHYSIS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; WEIGHT REDUCTION;

ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CALCIUM; COLLAGEN TYPE I; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MALE; OSTEOCALCIN; OSTEOGENESIS; PEPTIDES; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84861876392     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010; 8: 178-184.
2. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
3. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblasts differentiation. Endocrinology 2002; 143: 2376-2384.
4. Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 2003; 142: 29-34.
5. Kawaguchi H, Akune T, Yamaguchi M, et al. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 2005; 23: 275-279.
6. Stunes AK, Westbroek I, Gustafsson BI, et al. The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord 2011; 11: 11.
7. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004; 183: 203-216.
8. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007; 148: 2669-2680.
9. Syversen U, Stunes AK, Gustafsson BI, et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPARα) agonist fenofibrate and the PPARγ agonist pioglitazone. BMC Endocr Disord 2009, 9: 10.
10. Zanchi A, Pechere-Bertschi A, Burnier M, Bonny O. Effects of pioglitazone on renal calcium excretion. J Clin Endocrinol Metab 2011; 96: E1482-E1485.
11. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93: 1696-1701.
12. Gruntmanis U, Fordan S, Ghayee HK, et al. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010; 86: 343-349.
13. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 1305-1310.
14. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007; 92: 3523-3530.
15. Mavrakanas T, Cheva A, Kallaras K, Karkavelas G, Mironidou-Tzouveleki M. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats. Pharmacology 2010; 86: 85-91.
16. Schafer A, Vogt C, Fraccarollo D, et al. Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J Physiol Pharmacol 2010; 61: 45-52.
17. Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997; 272: E989-E996.
18. Zhang L, Liu Y, Wang D, et al. Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats. Acta Diabetol 2009; 46: 119-126.
19. Ward DT, Yau SK, Mee AP, et al. Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J Am Soc Nephrol 2001; 12: 779-790.
20. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 2010; 20: 683-690.
21. Erdal N, Gurgul S, Kavak S, Yildiz A, Emre M. Deterioration of bone quality by streptozotocin (STZ)-induced type 2 diabetes mellitus in rats. Biol Trace Elem Res 2011; 140: 342-353.
22. Sardone LD, Renlnd R, Willett TL, Fantus IG, Grynpas MD. Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes 2011; 60: 3271-3278.
23. Konturek PC, Brzozowski T, Burnat G, et al. Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats. J Physiol Pharmacol 2010; 61: 429-436.